Bajaj Finserv Ltd (BOM:532978) reports a 10% rise in total income and strategic shifts in product offerings to drive future growth.

Bajaj Health has also extended the offer for Pimavanserin to several leading pharma companies to ensure availability in ...

Its consolidated total income rose by 10 per cent to Rs 32,042 crore in the reporting quarter (Q3FY25), from Rs 29,038 crore ...

Bajaj Finserv on Thursday reported a 3% year-on-year (YoY) rise in its consolidated profit to Rs 2,231 crore for the December ...

Take your experience further with Mint Premium- access thought-provoking opinions, expert analysis and in-depth insights ...

Take your experience further with Mint Premium- access thought-provoking opinions, expert analysis and in-depth insights ...

During the quarter, the company reported a net profit of ₹2,231 crore up from ₹2,158 in the corresponding quarter of the ...

Mumbai: Bajaj Healthcare Limited has announced that it has received approval from the Drug Controller General of India (DCGI) ...

Net interest income (NII) grew 23% YoY to ₹9,382 crore, while new loans booked hit a record high of 12.06 million, up 22% ...

Bajaj Healthcare has received approval from India's Drug Controller General to manufacture Pimavanserin, a drug for Parkinson's-related hallucinations and delusions. Pimavanserin, already popular in ...

Bajaj Finserv's consolidated net profit increased 3.4% to Rs 2,231 crore on 10.34% rise in total income to Rs 32,041.81 crore in Q3 FY25 over Q3 FY24.